7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptanoic acid | 121099-56-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptanoic acid
• CAS: 121099-56-7
• 化学式: C₂₂H₂₇FO₃
• 分子量: 358.453
• InChiKey: WBVXKKZNMXLFPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptanoic acid 、 异丙胺 在 氯化亚砜 、 三乙胺 作用下， 以 N-甲基乙酰胺 、 盐酸 、 二氯甲烷 为溶剂， 生成 N-isopropyl-7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptane amide
  参考文献：
  名称：

  Phenol derivatives, their production and use

  摘要：

  具有以下一般式的新型酚衍生物：##STR1## 其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、X、Y和n如规范中定义的那样，具有对大脑、心脏、肾脏和肺部循环系统疾病、呼吸系统疾病、过敏、过敏性休克、内毒素休克、炎症等的治疗和预防活性，以及对肿瘤细胞血管化的抑制活性。

  公开号：

  US05162571A1
• 作为产物：
  描述：

  2,4,5-三甲酚 、 7-(4-fluorophenyl)-7-hydroxyheptanoic acid 在 三氟化硼乙醚 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 6.0h， 以78%的产率得到7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptanoic acid
  参考文献：
  名称：

  Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives

  摘要：

  Consideration of possible structural similarities between thromboxane A2 and the hydroquinone form of (R)-(+)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid (R-(+)-AA-2414) led to the development of a new series of thromboxane A2/prostaglandin H-2 (TXA2/PGH2) receptor antagonists, namely 7-(4-fluorophenyl)-7-(2-hydroxyphenyl)heptanoic acids (I). These compounds were found to be potent TXA2/PGH2 receptor antagonists. Compounds having either a carbonyl or a hydroxymethyl group at the para-position of the phenolic hydroxy group exhibited most potent activities in this series. Compounds 14, 15, 18, and 26 inhibited the specific binding of [H-3]U-46619 to guinea pig platelet membranes (IC50 = 4.4, 80, 32, and 13 nM, respectively), and also inhibited U-46619-induced human platelet aggregation (IC50 = 310, 69, 79, and 78 nM, respectively). Comparison of the UV spectra of the compounds with a carbonyl group at the para-position of phenolic hydroxy group revealed that the activity tended to increase in accordance with a decrease in the torsional angle between the carbonyl group and the phenol ring. These results suggested that the spacial location of the carbonyl and hydroxymethyl oxygen are important for significant increase in activity and that the carbonyl and hydroxymethyl oxygen at the para-position of the phenolic hydroxy group might interact with one of the TXA2/PGH2 receptor sites.

  DOI：

  10.1021/jm00090a009
• 作为试剂：
  描述：

  2,4,5-三甲酚 、 7-(4-fluorophenyl)-7-hydroxyheptanoic acid 、 trifluoroborane diethyl ether 在 水 、 乙酸乙酯 、 magnesium sulfate 、 ethyl acetate n-hexane 、 7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptanoic acid 作用下， 以 甲苯 为溶剂， 反应 6.0h， 以to obtain 7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptanoic acid (4.5 g) (Compound 1)的产率得到7-(4-fluorophenyl)-7-(2-hydroxy-3,5,6-trimethylphenyl)heptanoic acid
  参考文献：
  名称：

  Phenol derivatives, their production and use

  摘要：

  一种新的苯酚衍生物，其通式为：##STR1## 其中R.sup.1，R.sup.2，R.sup.3，R.sup.4，R.sup.5，X，Y和n如规范中所定义，具有治疗和预防脑、心、肾和肺循环系统疾病、呼吸系统疾病、过敏、过敏性休克、内毒素休克、炎症等方面的治疗和预防作用，以及对肿瘤细胞血管化的抑制作用。

  公开号：

  US05162571A1

文献信息

• Process of preparing diphenylmethane derivatives
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0537954A1

  公开（公告）日：1993-04-21

  A diphenylmethane compound (III) can be produced in a good yield by allowing a phenol compound (I) to react with a stilbene compound (II) in the presence of methanesulfonic acid

  在甲磺酸存在下，让苯酚化合物（I）与二苯乙烯化合物（II）反应，可以生产出产率很高的二苯基甲烷化合物（III）。
• JPH02152940A
  申请人：——

  公开号：JPH02152940A

  公开（公告）日：1990-06-12
• US5162571A
  申请人：——

  公开号：US5162571A

  公开（公告）日：1992-11-10
• Synthesis and thromboxane A2/prostaglandin H2 receptor antagonistic activity of phenol derivatives
  作者：Shoji Fukumoto、Mitsuru Shiraishi、Zenichi Terashita、Yasuko Ashida、Yoshiyuki Inada

  DOI：10.1021/jm00090a009

  日期：1992.6

  Consideration of possible structural similarities between thromboxane A2 and the hydroquinone form of (R)-(+)-7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid (R-(+)-AA-2414) led to the development of a new series of thromboxane A2/prostaglandin H-2 (TXA2/PGH2) receptor antagonists, namely 7-(4-fluorophenyl)-7-(2-hydroxyphenyl)heptanoic acids (I). These compounds were found to be potent TXA2/PGH2 receptor antagonists. Compounds having either a carbonyl or a hydroxymethyl group at the para-position of the phenolic hydroxy group exhibited most potent activities in this series. Compounds 14, 15, 18, and 26 inhibited the specific binding of [H-3]U-46619 to guinea pig platelet membranes (IC50 = 4.4, 80, 32, and 13 nM, respectively), and also inhibited U-46619-induced human platelet aggregation (IC50 = 310, 69, 79, and 78 nM, respectively). Comparison of the UV spectra of the compounds with a carbonyl group at the para-position of phenolic hydroxy group revealed that the activity tended to increase in accordance with a decrease in the torsional angle between the carbonyl group and the phenol ring. These results suggested that the spacial location of the carbonyl and hydroxymethyl oxygen are important for significant increase in activity and that the carbonyl and hydroxymethyl oxygen at the para-position of the phenolic hydroxy group might interact with one of the TXA2/PGH2 receptor sites.
• Phenol derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05162571A1

  公开（公告）日：1992-11-10

  Novel phenol derivatives of the general formula: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, X, Y and n are as defined in the specification, which have therapeutic and prophylactic activities against cerebral, cardiac, renal and pulmonary circulatory system diseases, respiratory diseases, allergy, anaphylactic shock, endotoxin shock, inflammation and the like as well as inhibiting activities against vascularization by oncocytes.

  具有以下一般式的新型酚衍生物：##STR1## 其中R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5、X、Y和n如规范中定义的那样，具有对大脑、心脏、肾脏和肺部循环系统疾病、呼吸系统疾病、过敏、过敏性休克、内毒素休克、炎症等的治疗和预防活性，以及对肿瘤细胞血管化的抑制活性。